Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance.

Détails

ID Serval
serval:BIB_51383799B86D
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance.
Périodique
Cancer Metastasis Reviews
Auteur⸱e⸱s
Kandalaft L.E., Motz G.T., Duraiswamy J., Coukos G.
ISSN
1573-7233 (Electronic)
ISSN-L
0167-7659
Statut éditorial
Publié
Date de publication
2011
Volume
30
Numéro
1
Pages
141-151
Langue
anglais
Notes
Publication types: Journal Article ; Review Publication Status: ppublish
Résumé
In the past few years, cancer immunotherapies have produced promising results. Although traditionally considered unresponsive to immune therapy, increasing evidence indicates that ovarian cancers are, in fact, immunogenic tumors. This evidence comes from diverse epidemiologic and clinical data comprising evidence of spontaneous antitumor immune response and its association with longer survival in a proportion of ovarian cancer patients; evidence of tumor immune evasion mechanisms and their association with short survival in some ovarian cancer patients; and finally pilot data supporting the efficacy of immune therapy. Below we will discuss lessons learned on the biology underlying ovarian cancer immune rejection or tolerance and we will discuss its association with clinical outcome. We will discuss the role of angiogenesis and the tumor endothelium on regulation of the antitumor immune response with a special emphasis on the role of vascular endothelial growth factor (VEGF) in the suppression of immunological processes, which control tumor progression and its unique crosstalk with endothelin systems, and how their interactions may shape the antitumor immune response. In addition, we will discuss mechanisms of tumor tolerance through the suppression or exhaustion of effector cells and how these could be countered in the clinic. We believe that understanding these pathways in the tumor microenvironment will lead to novel strategies for enhancing ovarian cancer immunotherapy.
Mots-clé
Animals, Antigens, CD/immunology, Apoptosis Regulatory Proteins/immunology, Endothelial Cells/immunology, Endothelial Cells/metabolism, Female, Humans, Immune Tolerance, Immunologic Surveillance/immunology, Indoleamine-Pyrrole 2,3,-Dioxygenase/immunology, Ovarian Neoplasms/immunology, Programmed Cell Death 1 Receptor, Signal Transduction/immunology, Tumor Escape, Tumor Microenvironment/immunology
Pubmed
Web of science
Création de la notice
14/10/2014 12:42
Dernière modification de la notice
20/08/2019 15:06
Données d'usage